成人恶性肿瘤大剂量化疗后自体骨髓移植(ABMT)及每日输注粒细胞集落刺激因子(G-CSF)。

K. Tobinai, K. Takeyama, A. Kohno, M. Hayashi, M. Narabayashi, K. Tamayose, M. Shimoyama
{"title":"成人恶性肿瘤大剂量化疗后自体骨髓移植(ABMT)及每日输注粒细胞集落刺激因子(G-CSF)。","authors":"K. Tobinai, K. Takeyama, A. Kohno, M. Hayashi, M. Narabayashi, K. Tamayose, M. Shimoyama","doi":"10.3960/jslrt1961.31.479","DOIUrl":null,"url":null,"abstract":"Fourteen adult patients with resistant malignant tumors (3 with malignant lymphoma, 3 with acute lymphocytic leukemia, 5 with recurrent breast cancer and 3 with germ cell tumor) received high dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF). All the 14 patients showed bone marrow engraftment. Median neutrophilic recovery over 500/cmm was 12 days after ABMT, and no life-threatening infection occurred during neutropenic period. As compared with literature controls of high dose chemotherapy followed by ABMT not using G-CSF in Western countries, our results showed earlier recovery of neutrophils. It is suggested that G-CSF may shorten neutropenic period after ABMT. Non-hematologic regimen-related toxicities were under control. No therapy-related death was observed. Disease oriented, multicenter phase II studies of high dose chemotherapy followed by ABMT and daily infusion of G-CSF are ongoing.","PeriodicalId":237003,"journal":{"name":"Journal of the Japan Society of the Reticuloendothelial System","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF) for malignant tumors in adults.\",\"authors\":\"K. Tobinai, K. Takeyama, A. Kohno, M. Hayashi, M. Narabayashi, K. Tamayose, M. Shimoyama\",\"doi\":\"10.3960/jslrt1961.31.479\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fourteen adult patients with resistant malignant tumors (3 with malignant lymphoma, 3 with acute lymphocytic leukemia, 5 with recurrent breast cancer and 3 with germ cell tumor) received high dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF). All the 14 patients showed bone marrow engraftment. Median neutrophilic recovery over 500/cmm was 12 days after ABMT, and no life-threatening infection occurred during neutropenic period. As compared with literature controls of high dose chemotherapy followed by ABMT not using G-CSF in Western countries, our results showed earlier recovery of neutrophils. It is suggested that G-CSF may shorten neutropenic period after ABMT. Non-hematologic regimen-related toxicities were under control. No therapy-related death was observed. Disease oriented, multicenter phase II studies of high dose chemotherapy followed by ABMT and daily infusion of G-CSF are ongoing.\",\"PeriodicalId\":237003,\"journal\":{\"name\":\"Journal of the Japan Society of the Reticuloendothelial System\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Japan Society of the Reticuloendothelial System\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3960/jslrt1961.31.479\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Japan Society of the Reticuloendothelial System","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt1961.31.479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

14例成年耐药恶性肿瘤患者(恶性淋巴瘤3例,急性淋巴细胞白血病3例,复发性乳腺癌5例,生殖细胞瘤3例)接受大剂量化疗+自体骨髓移植(ABMT) +每日输注粒细胞集落刺激因子(G-CSF)治疗。14例患者均有骨髓移植。中性粒细胞恢复超过500/cmm的中位数为ABMT后12天,中性粒细胞减少期未发生危及生命的感染。与西方国家不使用G-CSF的高剂量化疗后ABMT的文献对照相比,我们的结果显示中性粒细胞恢复得更早。提示G-CSF可缩短ABMT后中性粒细胞减少期。非血液学方案相关的毒性得到控制。未观察到治疗相关死亡。以疾病为导向的、多中心的高剂量化疗、ABMT和每日G-CSF输注的II期研究正在进行中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
High dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF) for malignant tumors in adults.
Fourteen adult patients with resistant malignant tumors (3 with malignant lymphoma, 3 with acute lymphocytic leukemia, 5 with recurrent breast cancer and 3 with germ cell tumor) received high dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF). All the 14 patients showed bone marrow engraftment. Median neutrophilic recovery over 500/cmm was 12 days after ABMT, and no life-threatening infection occurred during neutropenic period. As compared with literature controls of high dose chemotherapy followed by ABMT not using G-CSF in Western countries, our results showed earlier recovery of neutrophils. It is suggested that G-CSF may shorten neutropenic period after ABMT. Non-hematologic regimen-related toxicities were under control. No therapy-related death was observed. Disease oriented, multicenter phase II studies of high dose chemotherapy followed by ABMT and daily infusion of G-CSF are ongoing.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信